HVTN 705/Imbokodo HIV Vaccine trial will not continue to next phase in African women
The Desmond Tutu HIV Foundation greets with great disappointment yesterday’s announcement from Johnson & Johnson and partners that the Imbokodo study, a large-scale HIV vaccine proof-of-concept study (HVTN 705) did not show sufficient levels of efficacy to continue the trial to completion. The results showed that the Adenovirus26-based mosaic vaccine regimen, while safe, did not…